TMX-67TLS Phase3 study
Phase 3
- Conditions
- Hyperuricemia associated with cancer chemotherapy
- Registration Number
- JPRN-jRCT2080222348
- Lead Sponsor
- TEIJIN PHARMA LIMITED
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Patients with intermediate or high risk of tumor lysis syndrome (TLS)
Exclusion Criteria
1)Patients with diagnosis of Laboratory TLS (LTLS) or Clinical TLS (CTLS).
2)Patients with severe hepatic insufficiency.
3)Patients with severe renal insufficiency.
4)Performance status of 3 to 4.
etc
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method